Compare PGY & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PGY | IOVA |
|---|---|---|
| Founded | 2016 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 2021 | 2008 |
| Metric | PGY | IOVA |
|---|---|---|
| Price | $21.04 | $9.36 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 10 |
| Target Price | ★ $34.50 | $9.00 |
| AVG Volume (30 Days) | 2.0M | ★ 13.4M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 116.43 | 14.84 |
| EPS | ★ 0.77 | N/A |
| Revenue | ★ $1,301,360,000.00 | N/A |
| Revenue This Year | $14.27 | $47.74 |
| Revenue Next Year | $14.39 | $40.31 |
| P/E Ratio | $25.94 | ★ N/A |
| Revenue Growth | ★ 26.07 | N/A |
| 52 Week Low | $10.40 | $1.76 |
| 52 Week High | $44.99 | $9.36 |
| Indicator | PGY | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 52.43 | 67.59 |
| Support Level | $20.50 | $3.82 |
| Resistance Level | $23.45 | $9.36 |
| Average True Range (ATR) | 1.14 | 0.44 |
| MACD | -0.29 | -0.07 |
| Stochastic Oscillator | 44.98 | 82.86 |
Pagaya Technologies Ltd is a product-focused technology company. It uses machine learning, a vast data network, and an AI-driven approach to offer comprehensive consumer credit and residential real estate products for its partners, their customers, and investors. Its suite of products includes Decline Monetization, Dual Look, First Look, Affiliate Optimizer Engine, Direct Marketing Engine, and FastPass, providing lenders with an AI-powered credit and acquisition ecosystem that helps them approve more borrowers, capture more demand, and grow without adding risk. Geographically, the company generates maximum revenue from its business in the United States.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.